csl-limited-valuation-analysis-fy26

As of July 2026, CSL Limited (CSL.ASX) has undergone a significant valuation compression, characterized by a share price decline of approximately 55-57% over the previous 12 months Verified Answer #1. The company, which was historically considered a blue-chip defensive favorite on the ASX, has encountered a combination of internal operational issues and external market headwinds Verified Answer #1.

Performance and Drivers of Depreciation

Several primary factors have contributed to the depreciation of CSL's stock price Verified Answer #1.

• Impairment Charges and M&A Integration: A major portion of the decline is attributed to US$5 billion in non-cash impairments announced for FY26 and FY27 related to the CSL Vifor acquisition Verified Answer #1. Investors reacted negatively to poor synergy realization and the scale of these write-downs, which impacted the growth narrative of the acquisition Verified Answer #1.
• Earnings Misses and Guidance Downgrades: Investor confidence was affected by earnings downgrades, including FY26 revenue guidance of approximately US$15.2 billion and NPAT of approximately US$3.1 billion, both of which fell below market expectations Verified Answer #1.
• Leadership Instability: Uncertainty regarding the company's long-term strategic direction was created by the sudden departure of CEO Paul McKenzie in early 2026 and the subsequent appointment of an interim CEO Verified Answer #1.
• Competitive Pressures: Profitability has been weighed down by increased competition in the iron market affecting Vifor, as well as challenges within the CSL Behring plasma division regarding immunoglobulin margins Verified Answer #1.

Technical Valuation Status

From a technical perspective, indicators such as the Relative Strength Index (RSI) reached levels near 20–21 in early June 2026 Verified Answer #1. These levels suggest a deeply oversold status that has historically triggered short-covering rallies Verified Answer #1.